Insitro uses AI to accelerate drug discovery in partnership with major pharmaceutical companies.

Insitro, an AI company founded in 2018, is collaborating with pharmaceutical giants like Eli Lilly and Bristol Myers Squibb to accelerate drug discovery using machine learning. CEO Daphne Koller believes AI can help understand complex diseases and identify new treatments by analyzing vast biological data. Insitro aims to bridge the gap between computer scientists and medical researchers to develop drugs for metabolic, neurological, and degenerative diseases more efficiently.

4 months ago
20 Articles